五子衍宗方与左卡尼汀治疗男性不育症的Meta分析

doi:10.3969/j.issn.1006-5253.2018.04.002

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (1540 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically evaluate the efficacy of wuziyanzong and levocarnitine in the treatment of male infertility. Methods Based on the principles and methods of Cochrane systematic reviews, we searched PubMed, Embase, the Cochrane Library, EBSCO, CNKI, VIP, CBM and Wanfang databases from inception to July 2017 for randomized controlled clinical trials addressing the treatment of male infertility with wuziyanzong. According to the inclusion and exclusion criteria and retrieval strategies, we extracted the data, evaluated the quality of the included literature, and conducted meta-analysis using the RevMan 5.3 software. Results Four trials involving 324 patients were included. The results of meta-analysis showed that effectiveness rate(RR=1.25,95%CI:0.99~1.58,P=0.06), confirmed pregnancy rate(RR=1.76,95%CI:0.81~3.82,P=0.15), △semen volume(MD=-0.04,95%CI:-0.41~0.34,P=0.85), △sperm density(SMD=0.65,95%CI:-0.12~1.43,P=0.10), △grade A sperm rate(MD=1.89,95%CI:-10.41~14.20,P=0.76)and △grade A+B sperm rate(MD=3.42,95%CI:-5.00~11.84,P=0.43) of wuziyanzong group were not inferior to those of levocarnitine group, but △sperm motility of wuziyanzong group was inferior to that of levocarnitine group (MD=-12.42,95%CI:-22.06~ -2.78,P=0.01). Conclusion According to this evaluation system, wuziyanzong treatment of male infertility has some curative effect, but because of some limitations, it still needs large-scale randomized controlled clinical trial for verification according to dialectics of traditional Chinese medicine.

Key words： wuziyanzong levocarnitine male infertility oligospermia and asthenospermia Meta analysis

Received: 07 February 2018

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	He Fangxiang
	Mao Xiongwei
	Wu Hui

Cite this article:

He Fangxiang,Mao Xiongwei,Wu Hui. Meta-analysis of wuziyanzong and levocarnitine for male infertility[J]. journal1, 2018, 25(4): 245-249.

URL:

http://manu58.magtech.com.cn/Jwk_zgyytj/EN/10.3969/j.issn.1006-5253.2018.04.002 OR http://manu58.magtech.com.cn/Jwk_zgyytj/EN/Y2018/V25/I4/245

[1] ASRM.Diagnostic evaluation of the infertile male: a committee opinio[J]. Fertil Steril, 2015,103(3):e18-25.
[2] 中华医学会男科学分会.左卡尼汀在男性不育症中临床应用专家共识:2014版[J].中华男科学杂志,2015,21(1):82-85.
[3] 中国中西医结合学会男科专业委员会.男性不育症中西医结合诊疗指南:试行版[J].中国中西医结合杂志,2015,35(9):1034-1038.
[4] 秦国政,李日庆,裴晓华,等.《基于脾肾两虚夹瘀论治无症状性弱精子不育症》专家共识[J].中华中医药杂志,2016,31(6):2235-2238.
[5] 李宪锐,商建伟,丁劲,等.《傅青主男科》辨治男性不育症探讨[J].河南中医,2018,36(2):211-214.
[6] 周志娟,赵进,尧波.旴江名医黄调钧治疗男性不育症验案2则[J].山西中医药,2018,49(1):5-6.
[7] 周建甫,李倩,张秋红,等.补肾类中医药治疗男性不育症随机对照试验的系统评价[J].中华男科学杂志,2015,21(9):833-840.
[8] 安琪,邹练.五子衍宗丸治疗男性不育症的Meta分析[J].中国性科学,2015,24(1):84-89.
[9] 段晓明,徐计秀,赵双生.左旋肉碱加五子衍宗丸治疗少、弱精子症的临床疗效观察 [C].全国性医学学术会议, 2010 :285-286.
[10]崔刚,徐文华,武广平.五子衍宗口服液联合左卡尼汀治疗少精、弱精症的临床分[J].海南医学院学报,2011,17(3):347-349.
[11]刘峰.中西药治疗少弱精子症临床观察[J].中医中药,2011,18(2):94-95.
[12]商学军,莫敦胜,詹绪新,等.左卡尼汀在男性不育患者精子DNA损伤中的保护作用[J].第三军医大学学报,2015,37(15):1508-1512.
[13]张利,段晓明,徐计秀,等.左旋肉碱加五子衍宗丸治疗少弱精子症[J].中国中西医结合外科杂志,2010,16(5):535-537.
[14]曾杰,许明贺,焦薇薇,等.从健脾补肾立法论治男性不育症的辨证思路[J].中华中医药杂志,2018,33(1):182-184.
[15]曾杰,王杰,许明贺,等.健脾补肾法治疗男性不育症的抗氧化机制探讨[J].中国性科学,2018,27(2):93-95.
[16]安琪,邹练.生精类中成药治疗男性少、弱精子症的Network Meta分析和系统评价[J].生殖与避孕,2016,36 (1):42-48.
[17]阎基,王琦,朱斌,等.生精类中成药治疗男性少弱精子症的Meta分析[J].生殖与避孕,2018,36 (4):793-797.
[18]刘少华,崔岩,董欣荣,等.左卡尼丁对抗大鼠力竭运动损伤及保护肾脏的作用与机制[J].滨州医学院学报,2016,39(03):176-179.
[19]商学军,王修来,黄宇烽.肉碱与男性生殖[J].中华男科学杂志,2006,12(8):726-729.
[20]徐锦龙,姚莉莉,段宝忠,等.三七总皂苷预防髋关节置换术后深静脉血栓形成的Meta分析[J].中国医院统计,2018,25(2):85-88.